Portal de Periódicos da CAPES

Treatment of chronic hepatitis C in haemophilia patients

2000; Wiley; Volume: 6; Issue: 6 Linguagem: Inglês

10.1046/j.1365-2516.2000.00398.x

1365-2516

Karina Meijer, W. M. Smid, J. van der Meer,

Hepatitis B Virus Studies

HaemophiliaVolume 6, Issue 6 p. 605-613 Treatment of chronic hepatitis C in haemophilia patients K. Meijer, K. Meijer Division of Haemostasis, Thrombosis and Rheology, University Hospital Groningen, the NetherlandsSearch for more papers by this authorW. M. Smid, W. M. Smid Division of Haemostasis, Thrombosis and Rheology, University Hospital Groningen, the NetherlandsSearch for more papers by this authorJ. Van Der Meer, J. Van Der Meer Division of Haemostasis, Thrombosis and Rheology, University Hospital Groningen, the NetherlandsSearch for more papers by this author K. Meijer, K. Meijer Division of Haemostasis, Thrombosis and Rheology, University Hospital Groningen, the NetherlandsSearch for more papers by this authorW. M. Smid, W. M. Smid Division of Haemostasis, Thrombosis and Rheology, University Hospital Groningen, the NetherlandsSearch for more papers by this authorJ. Van Der Meer, J. Van Der Meer Division of Haemostasis, Thrombosis and Rheology, University Hospital Groningen, the NetherlandsSearch for more papers by this author First published: 05 September 2008 https://doi.org/10.1046/j.1365-2516.2000.00398.xCitations: 9 KarinaMeijer Division of Haemostasis, Thrombosis and Rheology, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Tel.: +31 50 3612791; fax: +31 50 3611790; e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Bibliography 1 Alter MJ, Kruszon-Moran D & Nainan OV et al. The prevalence of hepatitis C virus infection in the United States 1988 through 1994. N Engl J Med 1999; 341: 556–62. 2 Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570–83. 3 Makris M, Garson JA & Ring CJA et al. Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. Blood 1993; 81: 1898–902. 4 Fletcher ML, Trowell JM, Craske J, Pavier K & Rizza CR. Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients. Br Med J 1983; 287: 1754–7. 5 Kernoff PBA, Lee CA, Karayiannis P & Thomas HC. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 1985; 60: 469–79. 6 Garson JA, Tuke PW & Makris M et al. Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates. Lancet 1990; 336: 1022–5. 7 Tedder RS, Briggs M & Ring C et al. Hepatitis C antibody profile and viraemia prevalence in adults with severe haemophilia. Br J Haematol 1991; 79: 512–15. 8 Watson HG, Ludlam CA & Rebus S et al. Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates. Br J Haematol 1992; 80: 514–18. 9 Makris M, Preston FE & Triger DR et al. Hepatitis C antibody and chronic liver disease in haemophilia. Lancet 1990; 335: 1117–19. 10 Rumi MG, Colombo M, Gringeri A & Mannucci PM. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. Ann Intern Med 1999; 112: 379–80. 11 Brettler DB, Alter HJ, Dienstag JL, Forsberg AD & Levine PH. Prevalence of hepatitis C antibody in a cohort of hemophilia patients. Blood 1990; 76: 254–6. 12 Noel L, Guerois C, Maisonneuve P, Verroust F & Laurian Y. Antibodies to hepatitis C virus in haemophilia. Lancet 1989; 334: 560–560. 13 Ludlam CA, Chapman D, Cohen B & Litton PA. Antibodies to hepatitis C virus in haemophilia. Lancet 1989; 334: 560–1. 14 Troisi CL, Hollinger BF & Hoots WK et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993; 81: 412–18. 15 Mauser-Bunschoten EP, Bresters D & Van Drimmelen AAJ et al. Hepatitis C infection and viremia in Dutch hemophilia patients. J Med Virol 1995; 45: 241–6. 16 Lanotte P, Dubois F & Le Pogam S et al. The kinetics of antibodies against hepatitis C virus may predict viral clearance in exposed hemophiliacs. J Infect Dis 1998; 178: 556–9. 17 Chambost H, Gerolami V & Halfon P et al. Persistent hepatitis C virus RNA replication in haemophiliacs: role of co-infection with human immunodeficiency virus. Br J Haematol 1995; 91: 703–7. 18 Aguilar C & Lucia JF. Anti-HCV seroreversion in HIV-negative haemophiliacs. Br J Haematol 1996; 93: 497–8. 19 Ragni MV, Ndimbie OK, Rice EO, Bontempo FA & Nedjar S. The presence of hepatitis C virus (HCV) antibody in human immunodeficiency virus-positive hemophilic men undergoing HCV ‘seroreversion’. Blood 1993; 82: 1010–15. 20 Brettler DB, Mannucci PM & Gringeri A et al. The low risk of hepatitis C virus transmission among sexual partners of hepatitic C-infected hemophilic males: an international, multicenter study. Blood 1992; 80: 540–3. 21 Brackmann SA, Gerritzen A, Oldenburg J, Brackmann HH & Schneweis KE. Search for intrafamilial transmission of hepatitis C virus in hemophilia patients. Blood 1993; 81: 1077–82. 22 Pol S, Fontaine H & Carnot F et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C. A comparison between immunocompetent and immunocompromised patients. J Hepatol 1998; 29: 12–19. 23 Poynard T, Bedossa P & Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825–32.DOI: 10.1016/s0140-6736(96)07642-8 24 Meijer K, Haagsma EB, Kok Th, Schirm J, Smid WM & Van der Meer J. Natural history of hepatitis C in HIV negative patients with congenital coagulation disorders. J Hepatol 1999; 31: 400–6. 25 Lee CA. Investigation of chronic hepatitis C infection in individuals with haemophilia. Br J Haematol 1997; 96: 424–8. 26 Telfer P. Liver biopsy for haemophilic patients with chronic HCV infection. Br J Haematol 1997; 99: 237–41. 27 Hanley JP, Jarvis LM & Andrews J et al. Investigation of chronic hepatitis C infection in individuals with haemophilia: assessment of invasive and non-invasive methods. Br J Haematol 1996; 94: 159–65. 28 Wong VS, Baglin T & Beacham E et al. The role for liver biopsy in haemophiliacs infected with the hepatitis C virus. Br J Haematol 1997; 97: 343–7. 29 Ahmed MM, Mutimer DJ & Elias E et al. A combined management protocol for patients with coagulation disorders infected with hepatitis C virus. Br J Haematol 1996; 95: 383–8. 30 Eyster ME, Diamonstone LS & Lien J-M et al. Natural history of hepatitic C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. J Acquir Immune Defic Syndr, 1993; 6: 602–10. 31 Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G & Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994; 87: 555–61. 32 Makris M, Preston FE & Rosendaal FR et al. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996; 94: 746–52. 33 Colombo M, Mannucci PM & Brettler DB et al. Hepatocellular carcinoma in hemophilia. Am J Hematol 1991; 37: 243–6. 34 Preston FE, Dusheiko G & Giangrande PLF et al. Hepatocellular carcinoma in UK haemophiliacs. Br J Haematol 1995; 89: S9–S9. 35 Darby SC, Ewart DW & Giangrande PLF et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997; 350: 1425–31.DOI: 10.1016/s0140-6736(97)05413-5 36 Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM & Briët E. Mortality in patients with hemophilia. Ann Intern Med 1995; 123: 823–7. 37 Eyster ME, Fried MW, Di Bisceglie AM & Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood 1994; 84: 1020–3. 38 Telfer PT, Brown D, Devereux H, Lee CA & Dusheiko GM. HCV RNA levels and HIV infection: evidence for a viral interaction in haemophilia patients. Br J Haematol 1994; 88: 397–9. 39 Sabin CA, Telfer P, Phillips AN, Bhagani S & Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997; 175: 164–8. 40 Hanley JP, Dolan G & Day S. Interaction of hepatitis B and hepatitis C infection in haemophilia. Br J Haematol 1993; 85: 611–12. 41 Jarvis LM, Ludlam CA & Ellender JA et al. Investigation of the relative infectivity and pathogenicity of different hepatitis C virus genotypes in hemophiliacs. Blood 1996; 87: 3007–11. 42 Telfer PT, Devereux H & Savage K et al. Chronic hepatitis C virus infection in haemophilic patients: clinical significance of viral genotype. Thromb Haemost 1995; 74: 1259–64. 43 Preston FE, Jarvis LM & Makris M et al. Heterogeneity of hepatitis C virus genotypes in hemophilia: relationship with chronic liver disease. Blood 1995; 85: 1259–62. 44 Martinot-Peignoux M, Boyer N & Pouteau M et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998; 29: 214–23. 45 National Institutes of Health Consensus Development Conference. Panel statement on the management of hepatitis C. Hepatology 1997; 26 (Suppl. 1): 2S–10S. 46 European Association for the Study of the Liver EASL international consensus conference on hepatitis C. J Hepatol 1999; 30: 956–61. 47 Preston FE, Dusheiko G, Lee CA, Ludlam CA & Giangrande PLF. Guidelines on the diagnosis and management of chronic liver disease in haemophilia. Haemophilia 1995; 1 (Suppl. 4): 42–4. 48 Hanley JP, Jarvis LM & Andrews J et al. Interferon treatment for chronic hepatitis C infection in haemophiliacs—influence of virus load, genotype, and liver pathology on response. Blood, 1996; 87: 1704–9. 49 Peerlinck K, Willems M & Sheng L et al. Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with alpha-2b interferon is not a predictor for sustained response to treatment. Br J Haematol 1994; 86: 816–19. 50 Yoshikawa M, Fukui H & Kojima H et al. Interferon treatment of chronic hepatitis C in patients with hemophilia or von Willebrand’s disease in Japan. J Gastroenterol 1995; 30: 367–71. 51 Bresters D, Mauser-Bunschoten EP & Cuypers HTM et al. Long term treatment of chronic hepatitic C with interferon alfa-2b: disappearance of HCV-RNA in a pilot study of eight haemophilia patients. Gut 1993; Suppl.: S124–5. 52 Mauser-Bunschoten EP, Bresters D & Reesink HW et al. Effect and side-effects of alpha interferon treatment in haemophilia patients with chronic hepatitis C. Haemophilia 1995; 1: 45–53. 53 Pinilla J, Quintana M & Magallon M. High-dose and long-term treatment of α interferon in hemophilic patients with chronic C virus hepatitis. Blood 1998; 91: 727–8. 54 Makris M, Preston FE & Triger DR et al. A randomized controlled trial of recombinant interferon-α in chronic hepatitis C in hemophiliacs. Blood 1991; 78: 1672–7. 55 Makris M, Preston FE & Triger DR et al. Interferon alfa for chronic hepatitis C in haemophiliacs. Gut 1993; Suppl.: S121–3. 56 Telfer P, Devereux H & Colvin B et al. Alpha interferon for hepatitis C virus infection in haemophilic patients. Haemophilia 1995; 1: 54–8. 57 Rumi MG, Santagostino E & Morfini M et al. A multicenter controlled, randomized, open trial of interferon α2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Blood 1997; 89: 3529–33. 58 Poynard T, Leroy V & Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778–89. 59 Cammà C, Giunta M & Pinzello G et al. Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials. Am J Gastroenterol 1999; 94: 581–95. 60 Makris M & Preston FE. Interferon-α treatment and formation of factor VIII antibodies. Ann Intern Med 1997; 126: 829–829. 61 Castenskiold EC, Colvin BT & Kelsey SM. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy in a patient with haemophilia A. Br J Haematol 1994; 87: 434–6. 62 Stricker RB, Barlogie B & Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-α therapy. J Rheumatol 1994; 21: 350–2. 63 Mauser-Bunschoten EP, Damen M & Reesink HW et al. Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C. Ann Intern Med 1996; 125: 297–9. 64 Marcellin P, Boyer N & Gervais A et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med 1997; 127: 875–81. 65 Cammà C, Di Marco V & Iacono OL et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998; 28: 531–7. 66 Reichard O, Glaumann H & Frydén A et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30: 783–7. 67 International Interferon-α, Hepatocellular Carcinoma Study Group. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351: 1535–9.DOI: 10.1016/s0140-6736(98)07236-5 68 Ikeda K, Saitoh S & Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124–30. 69 Kasahara A, Hayashi N & Mochizuki K et al. 1998; 27: 1394–402. 70 Imai Y, Kawata S & Tamura S et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic Hepatitis C Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129: 94–9. 71 Reichard O, Norkrans G & Frydén A et al. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83–7.DOI: 10.1016/s0140-6736(97)06088-1 72 Poynard T, Marcellin P & Lee SS et al. Randomised trial of interferon α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–32.DOI: 10.1016/s0140-6736(98)07124-4 73 McHutchison JG, Gordon SC & Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–92. 74 Bontempo FA, Lewis JH & Gorenc TJ et al. Liver transplantation in hemophilia A. Blood 1987; 69: 1721–4. 75 Merion RM, Delius RE, Campbell DA & Turcotte JG. Orthotopic liver transplantation totally corrects factor IX deficiency in hemophilia B. Surgery 1988; 104: 929–31. 76 Delorme MA, Adams PC & Grant D et al. Orthotopic liver transplantation in a patient with combined hemophilia A and B. Am J Hematol 1990; 33: 136–8. 77 McCarthy M, Gane E & Pereira S et al. Liver transplantation for haemophiliacs with hepatitis C cirrhosis. Gut 1996; 39: 870–5. 78 Gordon FH, Mistry PK, Sabin CA & Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998; 42: 744–9. 79 Tradati F, Colombo M & Mannucci PM et al. A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C. Blood 1998; 91: 1173–7. Citing Literature Volume6, Issue6November 2000Pages 605-613 ReferencesRelatedInformation